# Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers

> **NCT01958060** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 35 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1034020
- **DRUG:** Placebo to BI 1034020

## Key facts

- **NCT ID:** NCT01958060
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2015-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01958060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01958060, "Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01958060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*